CTLA4Ig: bridging the basic immunology with clinical application

Immunity. 2006 Mar;24(3):233-8. doi: 10.1016/j.immuni.2006.03.001.


After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

MeSH terms

  • Abatacept
  • Animals
  • CD28 Antigens / physiology
  • CD40 Ligand / physiology
  • Humans
  • Immunoconjugates / pharmacology
  • Immunoconjugates / therapeutic use*
  • Lymphocyte Activation / drug effects
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology


  • CD28 Antigens
  • Immunoconjugates
  • CD40 Ligand
  • Abatacept